Clinical Trials Logo

Parathyroid Carcinoma clinical trials

View clinical trials related to Parathyroid Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05789680 Recruiting - Clinical trials for Parathyroid Carcinoma

European Multicentric Study on Parathyroid Carcinoma

EMS-PC
Start date: December 15, 2022
Phase:
Study type: Observational

The main aim of the study is to evaluate the incidence of post-operative diagnosis of PC and atypical parathyroid neoplasm in patients who underwent surgery for pHPT in different European centers using the EUROCRINE® database. Moreover, we aim to evaluate the peri-operative surgical characteristics, operation extent, postoperative morbidity, and outcomes in these patients category.

NCT ID: NCT03280264 Completed - Clinical trials for Primary Hyperparathyroidism

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Start date: August 30, 2017
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.

NCT ID: NCT03046524 Completed - Clinical trials for Parathyroid Carcinoma

Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior

Start date: October 6, 2015
Phase: N/A
Study type: Observational

Objectives: 1. Identify the clinical characteristics of parathyroid (PTH) cancer and PTH atypical neoplasms 2. Investigate if PTH carcinoma and atypical neoplasm present a biological behaviour and have a different impact on the health of the patients

NCT ID: NCT01460030 Completed - Clinical trials for Primary Hyperparathyroidism

An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism

Start date: November 2011
Phase: Phase 3
Study type: Interventional

This is an intra-individual titration study of KRN1493 to evaluate the safety and efficacy of KRN1493 for the treatment of hypercalcemia in patients with parathyroid carcinoma or intractable primary hyperparathyroidism (PHPT).

NCT ID: NCT00580320 Completed - Melanoma Clinical Trials

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Start date: September 2004
Phase: Phase 1
Study type: Interventional

Bortezomib will enhance the activity of dacarbazine against melanoma and soft tissue sarcoma. Weekly administration of the combination will prove to be feasible and tolerable at an appropriate dose.